Trump tariff 'panic': Drug maker Douglas Pharmaceuticals urges incentives not punishment

Trump tariff 'panic': Drug maker Douglas Pharmaceuticals urges incentives not punishment
Douglas Pharmaceuticals is currently developing three drugs. (Image: NZME/Getty/Supplied)
Rebecca Stevenson
A New Zealand pharmaceutical boss says the firm’s manufacture of three drugs could be impacted by the US’s planned 100% tariffs on patented pharmaceuticals. Douglas Pharmaceuticals' managing director, Jeff Douglas, said the proposed tariffs announced by United States President Donald Trump could be devastating for the industry and pose a considerable burden on patients. On Sept 26, Trump said that patented and branded pharmaceutical products would be subject to the tariff starting Oct 1, but drug makers with plans to b...

More Markets

Fletcher Building puts ‘noise’ in the past
Property

Fletcher Building puts ‘noise’ in the past

New directors say shareholders are right to expect more, and they intend to deliver.

More butter, more value: Fonterra’s $75m move to expand production
Primary Sector

More butter, more value: Fonterra’s $75m move to expand production

Fonterra Co-operative Group will invest $75 million to expand butter production at its Clandeboye site in South Canterbury.The move is part of the next phase of strategic investments by the co-op, signalled in its annual result.At the time, chief executive Miles Hurrell said the...

Air NZ expects 1H loss of $30m to $55m
Markets

Air NZ expects 1H loss of $30m to $55m

According to Air NZ, it had anticipated a 2% to 3% revenue uplift.

Alan Bougen corrects statement with regard to Comvita
Markets

Alan Bougen corrects statement with regard to Comvita

Bougen said some of his previous statements "may have been ambiguous".